Nutrilife S.R.L.

The research program at Nutrilife S.R.L. includes extensive studies on heart‑related conditions such as atherosclerosis, elevated lipoprotein(a), and major adverse cardiovascular events.

• Evaluating lepodisiran for reduction of MACE‑4 outcomes
• Testing muvalaplin to lower cardiovascular risk in patients with high Lp(a)
• Comparing tirzepatide with dulaglutide on major cardiovascular events
• Assessing orforglipron’s impact on cardiovascular outcomes in patients with atherosclerotic disease
• Investigating retatrutide for prevention of serious heart complications and kidney deterioration

These trials aim to improve prevention and treatment strategies for cardiovascular disease, offering new therapeutic options for patients across Europe.

In the department of Diabetes, Nutrition and Metabolic Diseases, the site focuses on obesity, overweight, and both type 1 and type 2 diabetes, seeking innovative ways to manage metabolic health.

• Studying eloralintide for significant weight loss in persistent obesity
• Comparing CagriSema with tirzepatide to improve blood sugar control and reduce body weight
• Evaluating orforglipron for better glycemic control in type 2 diabetes patients using insulin glargine
• Testing once‑weekly insulin icodec combined with insulin aspart for type 1 diabetes management
• Assessing NNC0487‑0111’s ability to reduce body weight in individuals with excess weight and type 2 diabetes

The overarching goal is to develop safe and effective therapies that address obesity and diabetes, improving quality of life for patients in Bucharest and beyond.